OBSV - ObsEva presents Yselty data in severe adenomyosis at ESHRE 37th Annual Meeting

ObsEva (OBSV) announces clinical data from a pilot study on Yselty (linzagolix) for the treatment of severe adenomyosis.Additionally, 52-week data from two Phase 3 studies of Yselty for the treatment of uterine fibroids, as well as results from an analysis of uterine contractility in women who participated in the IMPLANT 1 Phase 2 study of nolasiban for in-vitro fertilization ((IVF)) patients prior to embryo transfer ((ET)), were presented. Yselty for the Treatment of Severe Adenomyosis After 12 weeks, uterine size was significantly reduced, adenomyotic lesions regressed and symptoms, including pain and anemia, improved.Median serum estradiol was suppressed to 12 pg/mL after four weeks and maintained up to 12 weeks.No subjects reported uterine bleeding between weeks 4 to 12.Mean ± SD hemoglobin was 12.1 ± 2.0 at baseline and 12.8 ± 1.1 after 12 weeks. Yselty for the Treatment of Uterine Fibroids As previously reported in the PRIMROSE 1 and PRIMROSE

For further details see:

ObsEva presents Yselty data in severe adenomyosis at ESHRE 37th Annual Meeting